Skip Navigation



JAC Advance Access published online on June 16, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl251
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/2/367    most recent
dkl251v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gattringer, R.
Right arrow Articles by Thalhammer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gattringer, R.
Right arrow Articles by Thalhammer, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received December 11, 2005
Revised March 20, 2006
Accepted May 24, 2006

Original article

Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration

Rainer Gattringer 1 *, Brigitte Meyer 2, Gottfried Heinz 2, Claudia Guttmann 1, Markus Zeitlinger 3, Christian Joukhadar 3, Peter Dittrich 4, and Florian Thalhammer 1

1 Department of Internal Medicine I, Division of Infectious Diseases and Chemotherapy, Medical University of Vienna, Vienna, Austria
2 Department of Internal Medicine II, Division of Intensive Care Medicine, Medical University of Vienna, Vienna, Austria
3 Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
4 Department of Pharmacology, Karl-Franzens University, Graz, Austria

* To whom correspondence should be addressed.
Rainer Gattringer, E-mail: rainer.gattringer{at}meduniwien.ac.at


  Abstract

Objectives: Dosage recommendations for fosfomycin are available for haemodialysed patients but there are no data for patients undergoing continuous renal replacement therapy. Therefore, the present study was designed to determine the concentration-versus-time profile of fosfomycin in continuous venovenous haemofiltration (CVVH).

Patients and methods: A total of 12 anuric intensive care patients (10 males and 2 females) with suspected or proven infection requiring parenteral antibiotic therapy were included in the study. All patients underwent CVVH. Blood samples were drawn from the arterial (input) and venous (output) line of the extracorporeal circuit after application of a single dose of 8 g of fosfomycin. Ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the haemofilter. Fosfomycin in the samples was quantified by gas chromatography.

Results: The peak serum concentration was 442.7 ± 124 mg/L at the arterial port. The trough serum level was 103.1 ± 36.6 mg/L at the arterial port after 720 min. The mean value of the area under the concentration-versus-time curve from 0 to 12 h (AUC0-12) was 2159.4 ± 609.8 mg·h/L. Mean total removal of the drug was 76.7 ± 6.2%. The mean calculated clearance was 1.1 ± 0.2 L/h for CLHF. Mean CLtot was 6.4 ± 7.7 L/h.

Conclusions: A regimen of 8.0 g of fosfomycin every 12 h, which is usually used in patients with intact renal function, should be an appropriate antimicrobial treatment for patients undergoing CVVH.

Keywords: bactericidal agents; antibiotic agents; renal replacement therapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.